NASDAQ$ILMN

Illumina · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Reported record revenue driven by clinical applications and research.

Illumina reported a strong second quarter with record revenue of $1,126 million, a 78% increase compared to the prior year period. The company's performance was driven by clinical applications, including oncology and genetic disease testing, as well as research. As a result, Illumina raised its fiscal year 2021 financial guidance.

  • Revenue of $1,126 million, a 78% increase compared to the prior year period
  • GAAP net income of $185 million, or $1.26 per diluted share
  • Non-GAAP net income of $276 million, or $1.87 per diluted share
  • Raised fiscal year 2021 revenue growth guidance to 32%-34%

Headline financials

Total Revenue

$1.13B

Previous: $633M+77.9%
EPS (adj)

$1.87

Previous: $0.62+201.6%
Capital Expenditures

-$86M

Previous: -$79M-8.9%
Free Cash Flow

$99M

Previous: -$32M+409.4%
Net Income

$185M

Previous: $47M+293.6%
Operating Income

$187M

Previous: $96M+94.8%
Gross Profit

$802M

Previous: $428M+87.4%
Cash & Equivalents

$4.2B

Previous: $1.77B+137.1%
Total Assets

$8.68B

Previous: $7.25B+19.7%

Revenue & EPS history

Illumina · Revenue · Quarterly

$1.13B

Q2 2021+77.9%vs Q2 2020
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

Illumina · $147M total across 1 segment · Q1 2023

  • Service and Other Revenue
    $147M+5.0%

Forward guidance

For fiscal 2021, the company now expects year-over-year revenue growth in the range of 32% to 34%, GAAP earnings per diluted share of $4.69 to $4.89, and non-GAAP earnings per diluted share of $6.30 to $6.50.

Tailwinds

  • Year-over-year revenue growth in the range of 32% to 34%
  • GAAP earnings per diluted share of $4.69 to $4.89
  • Non-GAAP earnings per diluted share of $6.30 to $6.50

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

-0.8%

Avg return

Earnings day

-1.7%

Avg return

5 days after

-0.7%

Avg return

30 days after

35%

22 / 63 earnings

Positive

+21.1%

Q3 2025

Best reaction

-19.1%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.3%+12.5%+28.5%
Q4 2025-10.4%-12.9%-6.7%
Q3 2025+21.1%+23.7%+32.8%
Q1 2025-4.9%-1.7%+3.9%
Q3 2024+3.5%+0.9%-4.8%
Q2 2024+4.9%+7.0%+12.4%
Q1 2024-5.4%-9.5%-16.4%
Q4 2023-3.6%-6.4%-5.3%
Q3 2023-11.1%-11.9%+2.0%
Q2 2023-0.6%-5.9%-14.9%
Q1 2023-7.9%-10.3%-15.5%
Q4 2022-4.9%-5.8%-2.9%
Q3 2022+6.3%+3.3%+3.7%
Q2 2022-8.3%-3.3%-7.5%
Q1 2022-19.1%-28.6%-24.3%
Q4 2021-10.0%-7.0%-17.4%
Q3 2021-2.7%-5.8%-17.2%
Q2 2021-1.5%+0.4%-7.5%
Q1 2021-3.6%-6.6%-2.8%
Q4 2020+12.2%+9.5%-10.0%
Q3 2020-5.5%-4.2%+2.4%
Q2 2020-11.2%-14.9%-14.6%
Q1 2020-3.6%-2.3%+14.4%
Q4 2019-5.8%+2.5%-6.7%
Q3 2019-7.0%-3.5%+1.0%
Q2 2019-0.3%-1.2%-6.4%
Q1 2019-0.2%-0.8%-0.7%
Q4 2018-5.3%-1.7%+8.7%
Q3 2018-8.7%-7.0%-2.3%
Q2 2018+7.7%+10.4%+16.4%
Q1 2018-6.0%-0.6%+10.2%
Q4 2017-3.8%-8.9%-7.1%
Q3 2017-3.2%-0.7%+1.8%
Q2 2017+13.8%+11.9%+17.6%
Q1 2017+2.4%+2.6%-3.6%
Q4 2016+1.4%+1.8%+5.3%
Q3 2016-0.4%-1.1%-6.2%
Q2 2016+7.7%+10.4%+12.5%
Q1 2016-0.7%
Q4 2015-6.0%
Q3 2015-5.0%
Q2 2015-9.4%
Q1 2015-1.6%
Q4 2014-1.9%
Q3 2014+8.9%
Q2 2014-2.6%
Q1 2014+8.8%
Q4 2013+4.6%
Q3 2013+10.6%
Q2 2013+9.1%
Q1 2013+11.3%
Q4 2012-3.6%
Q3 2012-1.1%
Q2 2012-2.7%
Q1 2012-1.9%
Q1 2011-3.5%
Q4 2011-4.1%
Q4 2008-4.1%
Q3 2010+2.2%
Q3 2011+2.2%
Q2 2010+3.6%
Q2 2011+3.6%
Q4 2010+3.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro